Niki BioSolutions,

Niki BioSolutions, EBIT per Employee

EBIT per Employee of Niki BioSolutions, (NIKI) as of Oct 18, 2026.

EBIT per Employee

-USD

Last updated:

EBIT per Employee of Niki BioSolutions, is 2026 - USD. EBIT per Employee of Niki BioSolutions, was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Niki BioSolutions, Stock analysis

What does Niki BioSolutions, do? Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company based in Princeton, US, focused on developing therapeutic products for oncology and infectious diseases. The company operates through a pipeline including SACT-1 (Phase 1 for neuroblastoma), ALS-4 (Phase 1 for bacterial infections), and preclinical candidates like SACT-COV19 and ALS-1 targeting coronavirus and MRSA. It was formerly Aptorum Group Limited, rebranding in July 2026 following its listing on 17 July 2026. Niki BioSolutions, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Niki BioSolutions, stock

On Eulerpool you can find the complete historical development of EBIT per Employee Niki BioSolutions, since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Niki BioSolutions, historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Niki BioSolutions,

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Niki BioSolutions,